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Northern England
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Abstract
Background: The aetiology of neuroblastic tumours is unclear with both genetic and environmental factors implicated.
The possibility that an infectious agent may be involved has been suggested. ‘Temporal clustering’ occurs if cases display
an irregular temporal distribution and may indicate the involvement of an agent that exhibits epidemicity. We tested for
the presence and nature of temporal clustering using population-based data from northern England.
Methods: We extracted all cases of neuroblastic tumours diagnosed in children and young adults aged 0–24 years
during 1968–2011 from the Northern Region Young Persons’ Malignant Disease Registry. This is a population-based
registry, covering a population of approximately 900,000 young persons, and includes all cases resident in northern
England at the time of diagnosis. Tests for temporal clustering were applied using a modified version of the
Potthoff-Whittinghill method. Estimates of extra-Poisson variation (β^) and standard errors (SEs) were obtained.
Results: 227 cases of neuroblastic tumours were diagnosed during the study period. All the analyses between
fortnights and between months found significant extra-Poisson variation, with β^ =0.846 (SE = 0.310, P = 0.004)
for the analysis between fortnights within months. Restricting the analyses to the 76 cases diagnosed at ages
less than 18 months showed significant extra-Poisson variation between fortnights within months (β^ =1.532,
SE = 0.866, P = 0.038), but not between months. In contrast, analyses of cases aged 18 months to 24 years
showed significant extra-Poisson variation between quarters within years, as well as over shorter timescales.
Conclusions: Transient environmental agents may be involved in the aetiology of neuroblastic tumours. The initiating
factor might be a geographically-widespread agent that occurs in ‘mini-epidemics’.
Keywords: Epidemiology, Neuroblastic tumours, Temporal clustering
Background
Both genetic and environmental factors are likely to be in-
volved in the aetiology of neuroblastic tumours. Increased
risk has been associated with congenital abnormalities,
germline ALK and PHOX2B gene mutations, gestational
diabetes, both high and low birth weight, maternal an-
aemia during pregnancy and neonatal respiratory distress
with a low 1-min Apgar score [1–10]. A number of studies
have suggested various environmental risk factors. Both
prenatal and early-life exposures have been postulated. In
some (but not all) studies an increased risk of neuroblastic
tumours has been reported for families with higher num-
bers of siblings, parental alcohol consumption, maternal
hair dye use, vaginal infections during pregnancy, paternal
exposure to certain chemicals, parental occupational elec-
tromagnetic field exposure, other parental occupational
exposures, residential exposure to pesticides, ambient air
toxic exposures during pregnancy, maternal use of certain
medications or recreational drugs and smoking during
pregnancy [11–28]. In contrast, other studies found pro-
tective effects for childhood infectious diseases, breast-
feeding, prenatal vitamin supplements, maternal history of
previous fetal loss, folic acid food fortification and allergic
disease, and Down Syndrome in the child [12, 29–35].
The present study is focused on the detection of irregular
temporal occurrences of neuroblastic tumours. A general
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irregular temporal distribution of cases that is not limited
to one particular time of year is known as ‘temporal
clustering’. This type of clustering could arise because
there are a small number of periods with greatly in-
creased incidence or a large number of periods with
moderately increased incidence. The presence of such
clustering would be consistent with the involvement of
a temporally varying environmental agent in aetiology.
Putative exposures include atmospheric pollutants and
infections. It is plausible that, in certain circumstances,
infections may be both a risk factor and also convey
protection (e.g., by immune stimulation). Thus it
would be possible that infections may contribute to
both temporal excesses and deficits. We used a re-
cently developed methodology to analyse population-
based data on incident cases of neuroblastic tumours
from a region that has a relatively stable population,
with ethnic homogeneity and low rates of migration
into or out of the area [36–38].
Methods
All cases aged 0–24 years, diagnosed with a neuroblastic
tumour (neuroblastoma, ganglioneuroblastoma or ganglio-
neuroma) during the period 1968–2011 were extracted
from the Northern Region Young Persons’ Malignant
Disease Registry (NRYPMDR). This specialist registry was
initiated in 1968 and includes the geographical area com-
prising the counties of Northumberland, Tyne and Wear,
Durham, Teesside, and Cumbria (excluding Barrow-in–
Furness) in northern England. The population of the study
area aged 0–24 years is approximately 900,000 [39]. All ma-
lignancies in patients aged 0–24 years, resident in the re-
gion, are reported to the registry with a number of different
sources used to identify patients. Malignancies are notified
to the registry by consultants throughout the region and
there are regular cross-checks of data with regional and na-
tional cancer registries. The NRYPMDR has very good
completeness and ascertainment (>98 %) [40].
The data collected by the registry are exempt from indi-
vidual patient consent originally under Section 60 of the
UK Health and Social Care Act 2001, which has now been
superseded by Section 251 of the National Health Service
Act 2006. Ethical review was not required for the present
study, as the patient data used were deemed to be non-
identifiable.
Prior hypothesis
The following aetiological hypothesis was tested: a pri-
mary factor influencing the temporal occurrence of
neuroblastic tumours is related to exposure to a geo-
graphically widespread, irregularly temporally varying
environmental agent occurring either close to diagno-
sis or at similar times before diagnosis.
Statistical analysis
The statistical methods were similar to those used in a pre-
vious analysis of temporal clustering of disease [41]. A
modified version [42] of the Potthoff-Whittinghill tech-
nique [43, 44] was used to assess the degree of extra-
Poisson variation in the numbers of cases of neuroblastic
tumour per fortnight, calendar month, quarter of a year
and calendar year. Specifically, the numbers of cases were
assumed to follow a negative binomial distribution, with
the ratio of the variance to the expected number of cases
equal to a constant, namely 1 + β. If β equals 0, then the
numbers of cases are distributed as Poisson, whereas if β is
greater than 0, then the numbers of cases exhibit extra-
Poisson variation, i.e., are over-dispersed relative to Poisson.
The estimate of extra-Poisson variation, namely β^ , and its
standard error were based on the score statistic [42]. One-
sided tests were conducted for the presence of extra-
Poisson variation (i.e., β > 0), with P values assessed using
10000 simulations assuming β equal to zero. Findings with
P < 0.05 were judged to be statistical significant, while
values of P between 0.05 and 0.10 were judged to provide
weak evidence of an effect.
In order to remove the effects of longer-term variation
when looking for any short-term effects, analyses were con-
ducted conditional on the total number of cases within a
calendar month, quarter of a year (defined as January to
March; April to June; July to September; and October to
December), calendar year or total study period. Particular
attention was directed towards analyses based on the fol-
lowing hierarchy: between fortnights within calendar
months; between months within quarters of a year; between
quarters within years; and between years. Since the analysis
between fortnights within months was conducted condi-
tional on the total number of cases in each month, the re-
sults from this analysis are independent of those from the
analysis between months within quarters; the same applies
for the other analyses in this hierarchy, meaning that these
analyses can be interpreted independently of each other.
Descriptive analyses showed a preponderance of cases with
a diagnosis date of the 15th of the month, reflecting in-
stances where the day of the month was unknown. Conse-
quently, fortnights were defined pragmatically as the first
14 days of the calendar month versus the remainder of the
month from the 16th onwards, i.e., excluding the twelve
cases with a diagnosis date of the 15th. However, since there
is no reason to think that the month or year of diagnosis is
incorrect, all of the cases were included in the analyses be-
tween months, between quarters and between years.
The expected number of cases was assumed to be
proportional to the length of the period in question.
These expected numbers were standardised on the
basis that their total would equal the total number of
cases observed during the relevant period. For analyses
of extra-Poisson variation between years, it was not
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possible to take account of year-on-year variations in
population size because of a lack of data for the rele-
vant age range within the study area over the full study
period. However, based on population data for much of
the study area over 1987–2003 and estimated popula-
tion sizes for other years, sensitivity analyses were per-
formed in which expected numbers of cases per year
were assumed to be proportional to these population
sizes. No such adjustments were necessary for analyses
within years, since any variation in population size
within years is likely to be minimal.
Sensitivity analyses were also conducted for cases occur-
ring at ages less than 18 months, given that they form a
notable proportion of the cases diagnosed at ages under
25 years; for cases diagnosed at ages between 18 months
and 24 years inclusive; for males and females separately;
and including diagnoses of other peripheral nervous system
tumours [see Additional file 1].
Results
A total of 227 cases aged 0–24 years were diagnosed in
the study area during 1968–2011. Table 1 provides a
breakdown of these cases by gender, age at diagnosis
and period of diagnosis. Figure 1 shows the number of
cases by year of diagnosis. No long-term pattern is evi-
dent, as confirmed by the Potthoff-Whittinghill analyses
between years and between quarters of years (see lower
part of Table 2); sensitivity analyses based on estimated
annual population sizes gave similar results. In contrast,
all of the analyses between fortnights and between
months found significant extra-Poisson variation, with
β^ equal to 0.495 (SE 0.165, P = 0.002) for the analysis
between months within quarters and 0.846 (SE 0.310,
P = 0.004) for the analysis between fortnights within
months. Restricting the analyses to the 76 cases diagnosed
at ages less than 18 months also did not show significant
evidence of extra-Poisson variation between months, be-
tween quarters or between years. However, there was sig-
nificant extra-Poisson variation between fortnights (see
Table 3), with β^ equal to 1.532 (SE = 0.866, P = 0.038) for
the analysis between fortnights within months. For the 151
cases diagnosed at ages 18 months or later, there was sig-
nificant extra-Poisson variation between quarters within
years (β^ = 0.304, SE = 0.161, P = 0.035), as well as between
fortnights and between months (see Table 4).
Analyses by gender (Table 5) showed that the evi-
dence for extra-Poisson variation at ages 0–24 years
was largely restricted to the 118 cases among males. In
particular, β^ was significantly greater among males
than among females in all of the analyses between fort-
nights and between months, apart from the analysis
between fortnights within months where the evidence
for extra-Poisson variation was stronger among females
(P = 0.004) than among males (P = 0.12). Furthermore,
there was evidence of extra-Poisson variation in male
diagnoses between quarters within years (P = 0.003), but
not among females (P = 0.39). Further analysis showed that
the evidence of extra-Poisson variation among cases
diagnosed at ages less than 18 months was restricted
to males [see Additional file 2], whereas there tended
to be less evidence of differences in β^ between males
and females based on cases diagnosed at age 18 months
or older [see Additional file 3].
Including the 22 cases of other peripheral nervous cell
tumours (as defined in Additional file 1) diagnosed in
the study area at ages 0–24 years together with the 227
cases of neuroblastic tumours tended to weaken the evi-
dence for extra-Poisson variation in the analyses be-
tween fortnights and between months, with lower values
for β^ than before, e.g., 0.403 (SE = 0.153, P = 0.005) for
the analysis between months within quarters and 0.645
(SE = 0.289, P = 0.015) for the analysis between fortnights
within months. However, as before, all of the analyses
between fortnights and between months found signifi-
cant extra-Poisson variation (results not shown).
Discussion
This analysis has found evidence of temporal variation
of neuroblastic tumours in children and young adults
over short periods. After allowing for annual differences,
the numbers of cases in each quarter were as expected
under the Poisson assumption (i.e., no evidence of extra-
Poisson variation), although there was evidence of extra-
Table 1 Characteristics of cases of neuroblastic tumour in the
NRYPMDRa
No. of cases (%)
Overall (0–24 years) 227 (100 %)
Males 118 (52 %)
Females 109 (48 %)
Age at diagnosis:
<18 months 76 (33.5 %)
18 months – 4 years 99 (43.6 %)
5–24 years 52 (22.9 %)
Time period:
1968–1978 49 (21.6 %)
1979–1989 60 (26.4 %)
1990–2000 61 (26.9 %)
2001–2011 57 (25.1 %)
Mean Median Inter-quartile range
Age at diagnosis (years) 3.74 2.23 0.96–4.51
Annual number of cases 5.16 5 4–7
aBased on cases diagnosed during 1968-2011 inclusive
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Poisson variation between quarters within years among
males and at ages 18 months or older. Conversely the
number of cases in each fortnight and month showed
greater variation than would be expected under the
Poisson distribution (i.e., evidence of extra-Poisson
variation). These findings suggest that temporal clus-
tering of cases occurs in short periods of one month or
less, so indicating the involvement of transient envir-
onmental agents in aetiology. Furthermore, the magni-
tude of the extra-Poisson variation was lower when
cases of other peripheral nervous cell tumours were
added to the analysis, suggesting that the temporal clus-
tering reported here is specific to neuroblastic tumours
rather than to peripheral nervous cell tumours as a
whole.
To our knowledge there have been no previous studies
of temporal clustering of neuroblastic tumours. How-
ever, both spatial clustering and space-time clustering
have been analysed in earlier studies. Spatial clustering is
defined as an irregular spatial distribution of cases of a
disease and is interpreted as suggesting an environmen-
tal aetiology. Space-time clustering is defined as an ir-
regular distribution of cases of a disease in time and
space and is interpreted as suggesting an environmental,
possibly infectious aetiology. Previous studies from the
UK have not found evidence of space-time (based on
Fig. 1 Numbers of cases per year of neuroblastic tumours at ages 0–24 years in the NRYPMDR. Shown are the numbers of cases by calendar
year of diagnosis
Table 2 Analyses of temporal clustering of neuroblastic tumours at ages 0–24 years in the NRYPMDRa
β^b (SE)c
one-sided P-valued
Type of analysis Within months Within quarters Within years Within full study period
Between fortnightse 0.846 (0.310) 0.501 (0.108) 0.201 (0.051) 0.168 (0.044)
P = 0.004 P < 0.001 P < 0.001 P < 0.001
Between months 0.495 (0.165) 0.221 (0.073) 0.154 (0.062)
P = 0.002 P = 0.002 P = 0.008
Between quarters 0.201 (0.140) 0.020 (0.107)
P = 0.087 P = 0.39
Between years −0.299 (0.216)
P = 0.92
a)Based on cases diagnosed during 1968–2011 inclusive
b)β^ is the one-step estimate of β, the extra-Poisson variation, calculated as S/i(0) in the notation of Muirhead [42]
c)SE is the standard error of β^ in the absence of extra-Poisson variation, calculated as 1/√i(0) in the notation of Muirhead [42]
d)P-values have been calculated using 10000 simulations, assuming Poisson variation. All P-values are one-sided
e)Cases with a diagnosis date of the 15th of the month have been excluded from the analyses between fortnights but have been included in the other analyses
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both birth and diagnosis) or spatial clustering (based on
diagnosis) amongst cases of childhood neuroblastic tu-
mours [45–48]. An earlier study from the USA found
evidence of space-time clustering, based on birth but
not diagnosis [49], and a more recent study from Spain
found evidence of space-time clusters, based on diagno-
sis [50]. The lack of consistency in finding space-time
clustering for neuroblastic tumours may indicate that an
environmental agent only precipitates the onset of these
tumours in rare circumstances, with cases diagnosed at
disparate locations. However, the finding of temporal
clustering suggests that – within periods up to a few
months in length - diagnoses tend to occur at similar
times. It should be stressed that there is no reason to be-
lieve that these results are an artefact linked to access to
health care; specifically, the organisation of primary care
in England means that possible cases would present and
be referred to specialists without any tendency to cluster
over time.
A notable aspect of our findings was that – with the
exception of the analyses between fortnights within
months - the evidence for temporal clustering was
largely restricted to males. In particular, for the analyses
between months, the estimate of extra-Poisson variation
was significantly greater among males than among fe-
males. We had no prior expectation that the level of
temporal clustering would differ by gender. Further-
more, previous studies have not suggested that the aeti-
ology of childhood neuroblastic tumours differs between
males and females, although they have indicated that
such tumours are about 20 % more common among
males than among females [51, 52]. Consequently, our
Table 3 Analyses of temporal clustering of neuroblastic tumours at ages <18 months in the NRYPMDRa
β^b (SE)c
one-sided P-valued
Type of analysis Within months Within quarters Within years Within full study period
Between fortnightse 1.532 (0.866) 0.562 (0.255) 0.215 (0.082) 0.097 (0.044)
P = 0.038 P = 0.018 P = 0.016 P = 0.025
Between months 0.300 (0.387) 0.133 (0.118) 0.043 (0.062)
P = 0.18 P = 0.12 P = 0.18
Between quarters 0.214 (0.226) −0.032 (0.108)
P = 0.17 P = 0.54
Between years −0.403 (0.217)
P = 0.98
a)Based on cases diagnosed during 1968–2011 inclusive
b)β^ is the one-step estimate of β, the extra-Poisson variation, calculated as S/i(0) in the notation of Muirhead [42]
c)SE is the standard error of β^ in the absence of extra-Poisson variation, calculated as 1/√i(0) in the notation of Muirhead [42]
d)P-values have been calculated using 10000 simulations, assuming Poisson variation. All P-values are one-sided
e)Cases with a diagnosis date of the 15th of the month have been excluded from the analyses between fortnights but have been included in the other analyses
Table 4 Analyses of temporal clustering of neuroblastic tumours at ages 18 months to 24 years inclusive in the NRYPMDRa
β^b (SE)c
one-sided P-valued
Type of analysis Within months Within quarters Within years Within full study period
Between fortnightse 0.754 (0.417) 0.434 (0.145) 0.163 (0.060) 0.123 (0.044)
P = 0.036 P = 0.003 P = 0.008 P = 0.008
Between months 0.367 (0.215) 0.172 (0.084) 0.128 (0.062)
P = 0.046 P = 0.027 P = 0.023
Between quarters 0.304 (0.161) 0.143 (0.107)
P = 0.035 P = 0.091
Between years −0.060 (0.216)
P = 0.56
a)Based on cases diagnosed during 1968–2011 inclusive
b)β^ is the one-step estimate of β, the extra-Poisson variation, calculated as S/i(0) in the notation of Muirhead [42]
c)SE is the standard error of β^ in the absence of extra-Poisson variation, calculated as 1/√i(0) in the notation of Muirhead [42]
d)P-values have been calculated using 10000 simulations, assuming Poisson variation. All P-values are one-sided
e)Cases with a diagnosis date of the 15th of the month have been excluded from the analyses between fortnights but have been included in the other analyses
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findings on possible differences in temporal clustering
by gender should be interpreted with caution.
About a third of the cases studied here were diagnosed in
the first 18 months of life. Within this age group, there was
no evidence of temporal clustering between periods of a
month or more. However, temporal clustering was seen be-
tween fortnights within months. This suggests that a transi-
ent agent may be involved in aetiology and – given the
narrow age range – that exposure to this agent arose
shortly before diagnosis. In particular, exposure to such an
agent might act as a final “trigger” in the carcinogenic
process and lead to a clinically-recognisable tumour very
soon thereafter. In contrast, analysis of cases diagnosed at
ages between 18 months and 24 years found greater evi-
dence of temporal clustering over longer periods; specific-
ally, between quarters within years. An earlier study in
Germany [53] indicated possible differences in the aetiology
of childhood neuroblastic tumours between early and late-
stage disease at time of diagnosis. This raises the possibility
that temporal clustering may be more of a feature of high-
risk rather than low-risk disease. This topic will be ad-
dressed further in a future study. The suggestion of differ-
ences between the results for ages less than 18 months and
those for older ages might indicate that the lag time be-
tween any relevant exposure and diagnosis of the disease
varies by age. That said, the majority of cases diagnosed
after the first 18 months of life arose before 5 years
(see Table 1), so indicating that even for these cases the
lag period is likely to be relatively short; specifically, of
the order of months rather than years. This would fit
in with the findings for this older age group.
It is important to note that the present study did not ana-
lyse seasonal variation, i.e., whether neuroblastic tumours
diagnoses tend to occur more often than expected in the
same month of the same season each year. Instead, we fo-
cused on whether diagnoses tend to cluster together in
time, without regard for any periodicity in the pattern of
occurrence. A few previous studies have considered ana-
lyses of seasonality. A major study from the USA did not
find seasonal variation in month of diagnosis [54]. Another
study from Italy did not find overall seasonal variation of
date of diagnosis or birth, but this study did report seasonal
variation for birth in infants with stage 4 s disease [55].
Within the UK, a study based on the NRYPMDR did not
find any evidence of seasonality by either month of birth or
month of diagnosis in cases of sympathetic nervous system
tumours, most of which are neuroblastic tumours [56].
The present study has several limitations. By its nature, it
is not possible to identify specific agents that might be in-
volved in the aetiology of neuroblastic tumours, although it
Table 5 Analyses of temporal clustering of neuroblastic tumours at ages 0-24 years, separately for males and females in the
NRYPMDRa
β^b (SE)c
one-sided P-valued
Type of analysis Within months Within quarters Within years Within full study period
Between fortnightse Males 0.507 (0.423) 0.541 (0.162) 0.297 (0.063) 0.150 (0.044)
P = 0.12 P = 0.002 P < 0.001 P = 0.002
Females 2.095 (0.894) 0.157 (0.194) 0.036 (0.068) 0.005 (0.044)
P = 0.004 P = 0.19 P = 0.29 P = 0.39
Between months Males 0.831 (0.248) 0.417 (0.089) 0.204 (0.062)
P < 0.001 P < 0.001 P = 0.002
Females −0.160 (0.282) −0.027 (0.095) −0.058 (0.062)
P = 0.69 P = 0.59 P = 0.78
Between quarters Males 0.508 (0.170) 0.134 (0.107)
P = 0.003 P = 0.10
Females 0.039 (0.181) −0.064 (0.107)
P = 0.39 P = 0.68
Between years Males −0.435 (0.217)
P = 0.99
Females −0.185 (0.217)
P = 0.79
a)Based on cases diagnosed during 1968–2011 inclusive
b)β^ is the one-step estimate of β, the extra-Poisson variation, calculated as S/i(0) in the notation of Muirhead [42]
c)SE is the standard error of β^ in the absence of extra-Poisson variation, calculated as 1/√i(0) in the notation of Muirhead [42]
d)P-values have been calculated using 10000 simulations, assuming Poisson variation. All P-values are one-sided
e)Cases with a diagnosis date of the 15th of the month have been excluded from the analyses between fortnights but have been included in the other analyses
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does indicate facets of such agents (see below). Information
was not available on annual population sizes for the full
study period. However, sensitivity analyses based on es-
timated population sizes gave similar results to those
reported here; also, the analyses within years are un-
affected by variations in annual population sizes. It
might also be queried whether the quality of the data
has varied over the 44 year period of this study. How-
ever, a relatively recent histological review conducted
by one of the authors (DT) confirmed all of the cases
as being neuroblastic tumours. Furthermore, the diag-
noses of neuroblastic tumours have been made in ac-
cordance with internationally agreed criteria [57]. In
any case, any long-term changes are unlikely to influ-
ence analyses within periods of a year or less.
Since neuroblastic tumours are rare, the reliability of the
findings might be queried on the basis of the low annual
number of cases (about 5 per year in the study area) and
the possibility of errors in some dates of diagnosis. How-
ever, this is not supported by differences between the find-
ings at ages less than 18 months and those at older ages,
which indicate longer lag times at older ages. Furthermore,
analyses carried out of other cancers in the NRYPMDR
using the same methodology have – in most instances –
not found temporal clustering of the type reported here,
despite often being based on similar numbers of cases (un-
published results). Taken together with the common ap-
proach used to define diagnosis dates in this dataset, it is
unlikely that our results are due to data errors.
Our study has found that neuroblastic tumours occur
in ‘mini-epidemics’ that are geographically widespread
and occur at specific points in time. These findings sup-
port our prior hypothesis that a primary factor influen-
cing the temporal incidence of neuroblastic tumours is
related to exposure to an irregularly temporally varying
environmental agent occurring close to diagnosis or at
similar times before diagnosis. Examples of widespread
transient agents include infections and atmospheric pol-
lution. It is interesting to note that one study has sug-
gested that infections confer a protective effect on the
development of neuroblastic tumours [29]. Such an ef-
fect could lead to temporal deficits in incidence and thus
the occurrence of temporal clustering. This is important
in view of evidence that immunological surveillance
might be associated with the regression of stage 4 s neu-
roblastic tumours [58, 59] and that advanced, aggressive
cases of neuroblastic tumours evade immunological sur-
veillance [60, 61]. In contrast, a recent study has found
that exposure to ambient air toxics (carbon tetrachloride,
polycyclic aromatic hydrocarbons and hexavalent chro-
mium) during pregnancy was associated with an increased
risk of neuroblastic tumours [23], although there is cur-
rently little other evidence to support a role for atmospheric
pollution.
In conclusion, this study found new evidence for general
irregular (non-seasonal) temporal clustering among cases
of neuroblastic tumours. It suggests that there is support
for the involvement of an agent that occurs in geographic-
ally widespread mini-epidemics. Examples include certain
common infections (e.g., influenza) and atmospheric pollu-
tion. This result now needs to be confirmed by larger na-
tional and international studies. As with the “hygiene
hypothesis” for childhood leukaemia [62], future research
should seek to identify specific candidate agents which
could be protective or causative.
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